Lower utilization of home blood pressure monitoring in younger, poorly educated hypertensive males – real-life data

Chudek, Anna; Owczarek, Aleksander; Ficek, Joanna; Almgren-Rachtan, Agnieszka; Chudek, Jerzy

doi:10.1080/08037051.2019.1684818

Cited by 5 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concerning the above-mentioned differences between the sexes, we have tested a potentially distinct association between body mass, BMI/WC, and body fat depot, adjusted to declared physical activity and the prevalence of diabetes among men and women participating in a large survey (2017–2018) performed by physicians, with the participation of 14,200 unselected hypertensive outpatients [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

The Prevalence of Diabetes among Hypertensive Polish in Relation to Sex-Difference in Body Mass Index, Waist Circumference, Body Fat Percentage and Age

Bednarek

Owczarek

Chudek³

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

Background: Little is known about sex differences in the risk of type 2 diabetes (DM2) development related to body fat depot. The main aim of this study was to assess sex-specific differences in the prevalence of diabetes in the relation to body mass, body mass index (BMI), waist circumference (WC), and calculated body fat percentage (BF), adjusted by physical activity, in younger and older hypertensive adults. Subjects/Methods: The survey enrolled 12,289 adult hypertensive outpatients with body weight, height, and WC reported by their physicians across Poland. Prevalence of diabetes was plotted against body mass, BMI, WC, and calculated BF and adjusted by the self-reported level of physical activity. Results: In our cohort, younger women (<60 years) with BMI < 25.0 kg/m2 had lower adjusted prevalence of diabetes than corresponding men (3.4% vs. 6.5%), while among older (≥60 years) with BMI < 25.0 kg/m2, the prevalence of diabetes was greater in women than in men (19.4% vs. 11.2%). A 25% probability of diabetes was observed for younger women with lower BMI than younger men (32.1 kg/m2 and 35.3 kg/m2, respectively) and WC (100.7 cm and 116.1 cm, respectively) but greater BF (45.5% and 38.9%, respectively). The corresponding differences in BMI and WC in older ones were much smaller (27.6 kg/m2 and 27.2 kg/m2, respectively; 83.7 cm and 85.6 cm, respectively), but not for BF (40.7% and 30.1%, respectively). A doubling of diabetes probability (from 25% to 50%), adjusted by physical activity, was attributable to the lower increase in BMI and WC and BF in women than in men (6.3 vs. 9.8 kg/m2, 25.0 vs. 36.1 cm, and 6.5 vs. 10.8%, for younger, and 8.1 vs. 11.3 kg/m2, 26.2 vs. 73.2 cm and 8.8 vs. 13.3%, for older). Conclusions: This study shows a lower probability of diabetes in younger women than younger men with normal weight BMI ranges, adjusted to physical activity. This probability is greater for hypertensive women, regardless of age, due to the increase in BMI/WC and BF values adjusted for physical activity.

show abstract

Section: Introductionmentioning

confidence: 99%

The Prevalence of Diabetes among Hypertensive Polish in Relation to Sex-Difference in Body Mass Index, Waist Circumference, Body Fat Percentage and Age

Bednarek

Owczarek

Chudek³

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…[28] Among European and Asian countries, the rates of using HBPM varied considerably, ranging from 24.7% to 74.3%. [23][24][25][26] Two Chinese studies, which were multi-centered and recruited hypertensive patients from a few developed provinces or cities, showed that 28% of the hypertensive patients from these communities conducted HBPM at least once a week, [29] and 54% were observed among outpatients. [30] Many participants in our study were from large and mid-sized cities, which could represent the majority of hypertensive patients with high CVD risk in urban settings.…”

Section: Discussionmentioning

confidence: 99%

“…[20,21] Furthermore, current evidence on the effectiveness of HBPM use in hypertension control and management in the real world remains limited, especially among hypertensive patients at high risk of CVD-for whom identifying and treating risk factors could significantly reduce the risk. [22] Observational research has focused on the ownership of a monitoring device and the frequency of using HBPM, [22][23][24][25][26] whereas studies exploring the relationship between the practice of HBPM and hypertension management are still lacking.…”

Section: Introductionmentioning

confidence: 99%

Home Blood Pressure Monitoring and Its Association With Blood Pressure Control Among Hypertensive Patients With High Cardiovascular Risk in China

Li,

Tian,

Liu

et al. 2024

Cardiology Discovery

View full text Add to dashboard Cite

Objective: Home blood pressure monitoring (HBPM) is viewed as a facilitating factor in the initial diagnosis and long-term management of treated hypertension. However, evidence remains scarce about the effectiveness of HBPM use in the real world. This study aimed to examine the associations of HBPM use with blood pressure (BP) control and medication adherence. Methods: This prospective cohort study included hypertensive patients with high cardiovascular risk who were aged ≥50 years. At baseline, information about types of BP monitor, frequency of HBPM, perception of anti-hypertensive treatment, and measured office BP were collected. During the 1-year follow-up (visits at 1, 2, 3, 6, and 12 months), information on medication adherence was collected at each visit. The 2 major outcomes were BP control at baseline and medication adherence during the 1-year follow-up. A log-binomial regression model was used to examine the association between frequency of HBPM and outcomes, stratified by the perceptions of anti-hypertensive treatment. Results: A total of 5,363 hypertensive patients were included in the analysis. The age was (64.6 ± 7.2) years, and 41.2% (2,208) were female. Of the total patients, 85.9% (4,606) had a home BP monitor and 47.8% (2,564) had an incorrect perception of anti-hypertensive treatment. Overall, 24.2% (1,299) of patients monitored their BP daily, 37.6% (2,015) weekly, 17.3% (926) monthly, and 20.9% (1,123) less than monthly. At baseline, the systolic BP and diastolic BP were (146.6 ± 10.8) mmHg and (81.9 ± 10.6) mmHg, respectively, and 28.5% (1,527) of patients had their BP controlled. Regardless of whether the patients had correct or incorrect perceptions of anti-hypertensive treatment, there is no significant association between HBPM frequency and BP control at baseline. During the 1-year follow-up, 23.9% (1,280) of patients had non-adherence to medications at least once. In patients with an incorrect perception of anti-hypertensive treatment, those monitoring BP most frequently (daily) had the highest non-adherence rate (29.9%, 175/585). Compared with those monitoring their BP less than monthly, patients who monitored their BP daily were more likely not to adhere to anti-hypertensive medications (adjusted relative risk = 1.38, 95% confidence interval: 1.11–1.72, P = 0.004). Conclusions: HBPM performance among hypertensive patients in China is, in general, sub-optimal. No association was observed between using HBPM alone and hypertension control, indicating that the effects of HBPM could be conditional. Patients’ misconceptions about anti-hypertensive treatment may impair the role of BP monitoring in achieving medication adherence. Fully incorporating the correct perception of hypertension into the management of hypertensive patients is needed.

show abstract

“…However, we did not collect data concerning the comedication of other diseases than CVD, calcium channel blockers are frequently used in hypertensive patients. A recent large nationwide Polish cohort study, performed among 12,289 patients with hypertension showed that as much as 45.7% of them were prescribed one of calcium channel blockers containing medicines [27].…”

Section: Discussionmentioning

confidence: 99%

Assessment of the Tolerance of Dobenox Forte® in Patients with Chronic Venous Disease

Chudek,

Almgren-Rachtan,

Pastuszka

et al. 2024

Life

Self Cite

View full text Add to dashboard Cite

This prospective, observational, multicenter study assessed the tolerance of Dobenox Forte®, the first approved over-the-counter product containing calcium dobesilate, in 1795 outpatients with chronic venous disease (CVD) in daily clinical practice. In addition, the effectiveness (decrease in circumferences of a more affected limb at the ankle and middle part of the calf, and changes in the severity of CVD signs) was assessed. No adverse events related to use of the preparation were reported in a period of 64 ± 20 days. Dobenox Forte® use was associated with a reduction in calf circumference by 13.1 mm (95%CI: 12.2–14.1) and in ankle circumference by 9.7 mm (95%CI: 9.2–11.0) in patients reporting swelling of the lower legs (60.0% of the cohort). A reduction in calf and ankle circumference by at least 1 cm was achieved in 34.9% and 24.9% of patients, respectively. The percentages of patients reporting moderate to very severe lower limb heaviness decreased from 96.6% to 56.0%, calf cramps decreased from 91.0% to 41.0%, calf pain decreased from 89.2% to 43.7%, swelling decreased from 86.1% to 38.8%, and burning sensation that worsens when standing decreased from 79.0% to 33.7%. The medicinal product Dobenox Forte® is well tolerated by patients and seems to effectively reduce the symptoms of CVD.

show abstract

Lower utilization of home blood pressure monitoring in younger, poorly educated hypertensive males – real-life data

Cited by 5 publications

References 18 publications

The Prevalence of Diabetes among Hypertensive Polish in Relation to Sex-Difference in Body Mass Index, Waist Circumference, Body Fat Percentage and Age

The Prevalence of Diabetes among Hypertensive Polish in Relation to Sex-Difference in Body Mass Index, Waist Circumference, Body Fat Percentage and Age

Home Blood Pressure Monitoring and Its Association With Blood Pressure Control Among Hypertensive Patients With High Cardiovascular Risk in China

Assessment of the Tolerance of Dobenox Forte® in Patients with Chronic Venous Disease

Contact Info

Product

Resources

About